Delving into the Latest Updates on Haikou Kerui Hua Biotechnology Corporation Limited with Synapse

Overview

Tags

Immune System Diseases

Hemic and Lymphatic Diseases

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

survivin(Baculoviral IAP repeat-containing protein 5)	1

主要目的：确定SepB治疗c-Myc重排的复发性/难治性HGBCL的安全性和耐受性以及推荐II期剂量（RP2D）。次要目的：通过客观缓解率（ORR）、缓解持续时间（DoR）、临床获益率、总生存期和无进展生存期评价SepB的临床活性。探索性目的： 1、确定SepB的暴露量及其与临床结局的相关性。 2、评估生物标记物与SepB治疗后疗效之间的相关性。 3、评估细胞遗传学数据与SepB治疗后疗效之间的相关性。

[Translation]

Primary objective: To determine the safety and tolerability of SepB in the treatment of relapsed/refractory HGBCL with c-Myc rearrangement and the recommended phase II dose (RP2D). Secondary objectives: To evaluate the clinical activity of SepB by objective response rate (ORR), duration of response (DoR), clinical benefit rate, overall survival and progression-free survival. Exploratory objectives: 1. Determine the exposure of SepB and its correlation with clinical outcomes. 2. Evaluate the correlation between biomarkers and the efficacy of SepB treatment. 3. Evaluate the correlation between cytogenetic data and the efficacy of SepB treatment.

Start Date-

Sponsor / Collaborator

Beijing Percans Oncology Co., Ltd.

[+2]

100 Clinical Results associated with Haikou Kerui Hua Biotechnology Corporation Limited

Login to view more data

0 Patents (Medical) associated with Haikou Kerui Hua Biotechnology Corporation Limited

Login to view more data

100 Deals associated with Haikou Kerui Hua Biotechnology Corporation Limited

Login to view more data

100 Translational Medicine associated with Haikou Kerui Hua Biotechnology Corporation Limited

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data